Online inquiry

IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10045MR)

This product GTTS-WQ10045MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FN1 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10045MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13061MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ10706MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ4441MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ2212MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ8365MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ5361MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ2203MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ5789MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW